Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (dMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab

被引：0
|
作者：
Kristeleit, R. [1 ]
Matthews, C. [2 ]
Redondo, A. [3 ]
Huang, J. [4 ]
Eliason, L. [4 ]
Im, E. [4 ]
Brown, J. [5 ]
机构：
[1] NHS Fdn Trust, Guys & St Thomas Hosp, Dept Oncol, London, England
[2] Women & Infants Hosp Rhode Isl, Womens Oncol, Providence, RI 02908 USA
[3] Hosp Univ La Paz IdiPAZ, Med Oncol Dept, Madrid, Spain
[4] GlaxoSmithKline, Clin Sci, Waltham, MA USA
[5] Atrium Hlth, Levine Inst, Gy0ecol Oncol, Charlotte, NC USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.997
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
858P
引用
收藏
页码：S637 / S637
页数：1
相关论文
共 50 条
  • [1] PATIENT-REPORTED OUTCOMES (PROS) IN THE GARNET TRIAL IN PATIENTS (PTS) WITH ADVANCED OR RECURRENT MISMATCH REPAIR DEFICIENT/MICROSATELITE INSTABILITY-HIGH (DMMR/MSI-H) ENDOMETRIAL CANCER (EC) TREATED WITH DOSTARLIMAB
    Kristeleit, Rebecca
    Mathews, Cara
    Redondo, Andres
    Huang, Joice
    Eliason, Laurie
    Im, Ellie
    Brown, Jubilee
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A40 - A41
  • [2] Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab.
    Kristeleit, Rebecca Sophie
    Mathews, Cara Amanda
    Redondo, Andres
    Huang, Joice
    Eliason, Laurie
    Im, Ellie
    Brown, Jubilee
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Patient-reported outcomes (PRO) in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab in the GARNET trial.
    Kristeleit, Rebecca Sophie
    Mathews, Cara Amanda
    Redondo, Andres
    Huang, Joice
    Eliason, Laurie
    Im, Ellie
    Brown, Jubilee
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)
  • [4] Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab
    Kristeleit, Rebecca
    Mathews, Cara
    Redondo, Andres
    Boklage, Susan
    Hanlon, Jennifer
    Im, Ellie
    Brown, Jubilee
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (10) : 1250 - 1257
  • [5] Dostarlimab in advanced/recurrent (A/R) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study
    Oaknin, Ana
    Pothuri, Bhavana
    Gilbert, Lucy
    Sabatier, Renaud
    Ghamande, Sharad
    Gravina, Adriano
    Calvo, Emiliano
    Banerjee, Susana
    Mangan, Niamh
    Miller, Rowan E.
    Pikiel, Joanna
    Mirza, Mansoor R.
    Duan, Tao
    Zildjian, Sybil
    Zografos, Eleftherios
    Veneris, Jennifer
    Tinker, Anna V.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 133 - 134
  • [6] Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study.
    Oaknin, Ana
    Pothuri, Bhavana
    Gilbert, Lucy
    Sabatier, Renaud
    Ghamande, Sharad A.
    Gravina, Adriano
    Calvo, Emiliano
    Banerjee, Susana N.
    Miller, Rowan
    Pikiel, Joanna
    Mirza, Mansoor Raza
    Duan, Tao
    Zildjian, Sybil
    Zografos, Eleftherios
    Veneris, Jennifer Taylor
    Tinker, Anna
    Powell, Matthew A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Patient-reported outcomes (PROs) in patients (pts) with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
    Valabrega, G.
    Powell, M. A.
    Hietanen, S.
    Miller, E. M.
    Novak, Z.
    Holloway, R.
    Denschlag, D.
    Myers, T.
    Thijs, A. M.
    Pennington, K.
    Gilbert, L.
    Fleming, E.
    Copeland, L.
    Gogoi, R.
    Podzielinski, I.
    Cloven, N.
    Meyers, O.
    Garside, J.
    Mirza, M. R.
    Black, D.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S513 - S514
  • [8] PATIENT-REPORTED OUTCOMES IN THE GARNET TRIAL IN PATIENTS WITH ADVANCED OR RECURRENT MISMATCH REPAIR DEFICIENT SOLID TUMORS TREATED WITH DOSTARLIMAB
    Kristeleit, Rebecca
    Mathews, Cara
    Redondo, Andres
    Pennington, Kathryn
    Boklage, Susan
    Brown, Jubilee
    [J]. ONCOLOGY NURSING FORUM, 2022, 49 (02) : E57 - E58
  • [9] Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study
    Tinker, A. V.
    Pothuri, B.
    Gilbert, L.
    Sabatier, R.
    Brown, J.
    Ghamande, S.
    Mathews, C.
    O'Malley, D.
    Boni, V.
    Gravina, A.
    Banerjee, S.
    Miller, R.
    Pikiel, J.
    Mirza, M. R.
    Duan, T.
    Antony, G.
    Zildjian, S.
    Zografos, E.
    Veneris, J.
    Oaknin, A.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S798 - S799
  • [10] Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET
    Oaknin, A.
    Gilbert, L.
    Tinker, A. V.
    Sabatier, R.
    Boni, V.
    O'Malley, D. M.
    Ghamande, S.
    Duska, L.
    Ghatage, P.
    Guo, W.
    Im, E.
    Pothuri, B.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1166 - S1166
12345